Dosing Study of the V501 Product - Protocol 503: An Efficacy Study comparing two Doses of the V501 Product in Patients with certain Anterior Segment Eye Diseases
A dosing study of the ForSight Ocular System on Safety and Efficacy in Anterior Segment Eye Disease in Australia
ForSight VISION5, Inc
50 participants
Oct 30, 2012
Interventional
Conditions
Summary
Dosing study of sustained release Ocular System for treatment of Anterior Segment Eye Disease to determine Safety and Efficacy of the ForSight V501 Product.
Eligibility
Inclusion Criteria4
- Male or female, at least 18 years of age.
- Diagnosis of certain anterior segment eye diseases in eligible eye(s).
- Current treatment with monotherapy drops for anterior segment eye disease with a controlled IOP less than or equal to 18 mmHg in both eyes based on measurement at screening or review of medical record measurements.
- Other criteria as listed in Protocol.
Exclusion Criteria1
- Certain prior eye surgeries with different time windows for exclusion based on type of eye surgery.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ForSight Ocular System (drug/device combination product) will be placed in eye. Product contains prostaglandin which elutes with one of two dose over six month period. Dose is higher at beginning of use of product and gradually declines as drug elutes from product, as is typical for drug-eluting products. Maximum daily dose will not exceed levels tested in prior clinical studies. One dose will start under 100 mcg/day (maximum amount tested in prior clinical use) and will decline toward 0 mcg/day by end of study period. One dose will start under 50 mcg/day and will decline toward 0 mcg/day by end of study period.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000960853